A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas

NCT02812875 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

71

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors or Lymphomas

Interventions

DRUG: CA-170

Sponsor

Curis, Inc.